Ascendis Pharma (ASND) Stock Statistics & Valuation Metrics

Ascendis Pharma has a market cap or net worth of $10.45B. The enterprise value is $9.49B.

Ascendis Pharma has 60,970,566 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascendis Pharma’s return on equity (ROE) is 3.58 and return on invested capital (ROIC) is -37.00%.

The current PE Ratio of Ascendis Pharma is -20.36. Ascendis Pharma’s PEG ratio is -2.42.

In the last 12 months, Ascendis Pharma had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.

In the last 12 months, operating cash flow was -250.07M and capital expenditures -924.00K, giving a free cash flow of -250.99M billion.

Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ascendis Pharma upcoming earnings date is Sep 9, 2025, TBA Not Confirmed.

Ascendis Pharma as a current ratio of 1.17, with Debt / Equity ratio of -446.39%

In the past 12 months, Ascendis Pharma has paid 4.84M in taxes.

Ascendis Pharma EV to EBITDA ratio is -27.56, with an EV/FCF ratio of -25.99.

Ascendis Pharma has $559.54M in cash and marketable securities with €856.62M in debt, giving a net cash position of $297.07M billion.

Gross margin is 85.30%, with operating margin of -76.66%, and net profit margin of -103.97%.

The average price target for Ascendis Pharma is $223.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy